pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,657 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1864Endpoints1448Fierce Biotech764BioSpace754BioPharma Dive548raps249onclive165fda recalls
therapy area
allOncology12890Rare Disease3335Immunology3022Cardiology2848Hematology2298Pulmonology2254Vaccines
  • FDA approves Infilbray, first therapy for neurological symptoms of Type 3 Gaucher disease
    The U.S. Food and Drug Administration has approved Infilbray (venglustat) tablets for treating the neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 15…
    fda press · 4h agoApprovalPositive↗ source
  • GSK receives FDA accelerated approval for neladalkib (Nelkarmi) in ALK-positive lung cancer, second win from Nuvalent deal
    GSK announced that the FDA has granted accelerated approval to its tyrosine kinase inhibitor neladalkib, to be sold under the brand name Nelkarmi, for patients with ALK‑positive non‑small cell lung…
    BioSpace · 10h agoApprovalPositive
← prev
page 1 of 107
next →
120
fda medwatch115
globenewswire health73
fda press62
1854
Psychiatry & CNS1230
Ophthalmology1133
Endocrinology & Metabolism807
Pain791
Nephrology784
↗ source
  • Pfizer signs $2.6 billion deal with China's Starna to acquire in vivo CAR-T programs for autoimmune diseases
    Pfizer announced a $2.6 billion agreement with Chinese biotech Starna Therapeutics to obtain rights to three preclinical in vivo CAR-T candidates aimed at autoimmune diseases. The deal includes a…
    Fierce Biotech · 15h agoDealPositive↗ source
  • Pfizer signs $2.6 billion China deal to develop in-vivo CAR-T therapies for autoimmune disease
    Pfizer announced a collaboration with Chinese biotech Starna Therapeutics to pursue in-vivo CAR-T cell therapies aimed at autoimmune disorders. Under the agreement, Pfizer will receive exclusive r…
    BioPharma Dive · 7h agoDealPositive↗ source
  • Pfizer partners with China's Starna Therapeutics on up to $2.6B in vivo CAR-T deal for autoimmune diseases
    Pfizer announced a collaboration with Chinese biotech Starna Therapeutics to develop in vivo CAR-T therapies targeting autoimmune diseases. The agreement covers three preclinical CAR-T programs, w…
    BioSpace · 9h agoDealPositive↗ source
  • BMS reports early Alzheimer’s psychosis data for Cobenfy showing reduced hallucinations but safety concerns remain
    At the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, Bristol Myers Squibb presented early Phase 3 ADEPT data for KarXT, marketed as Cobenfy, in patients with Alzheimer’s disea…
    BioSpace · 7h agoPositive readoutNeutral↗ source
  • Government policies strain funding and operations for small biotech firms
    Cassel Salpeter's latest healthcare investment report says that recent government actions, including FDA staff reductions, slower federal research grants and higher tariffs, are creating a tough fu…
    BioSpace · 9h agoRegulatoryNegative↗ source
  • FDA rejects Summit Therapeutics' PD-1/VEGF bispecific ivonescimab after Phase 3 failure
    The U.S. Food and Drug Administration declined to grant approval for ivonescimab, a bispecific antibody that targets PD‑1 and VEGF and was being developed by Summit Therapeutics in collaboration wi…
    BioSpace · 12h agoRegulatoryNegative↗ source
  • Biogen's tau antisense therapy shows 38% slower decline in 2-year Alzheimer extension study
    Biogen presented new data from the open‑label extension of its phase 2 Celia trial at the CTAD 2026 conference. The update focused on the tau‑targeting antisense oligonucleotide, diranersen, admini…
    Fierce Biotech · 14h agoPositive readoutPositive↗ source
  • Priavoid’s Alzheimer’s drug misses primary goal in phase 2 trial, shows later cognitive benefit signal
    German biotech Priavoid reported that its oral all-D-peptide candidate, PRI-002, did not achieve the primary efficacy endpoint in the phase 2 PRImus-AD study of patients with mild cognitive impairm…
    Fierce Biotech · 19h agoNegative readoutNegative↗ source
  • Cognito Therapeutics' Phase 3 HOPE Study Misses Primary Goal but Shows Promise in Mild Alzheimer’s Patients
    Cognito Therapeutics announced that its phase 3 HOPE trial of Spectris AD, a home-based device delivering light and sound stimulation, did not achieve its primary efficacy endpoint. The trial enro…
    Fierce Biotech · 20h agoNegative readoutNeutral↗ source
  • Merck halts development of BTK inhibitor nemtabrutinib after safety concerns
    Merck announced it is ending development of the oral BTK inhibitor nemtabrutinib (MK-1026), which it acquired in the $2.7 billion ArQule purchase. The decision follows a recommendation from an ext…
    BioSpace · 8h agoRegulatoryNegative↗ source
  • FDA rejects Summit Therapeutics' lung cancer drug ivonescimab, citing insufficient survival benefit
    The U.S. Food and Drug Administration issued a complete response letter rejecting the lung‑cancer therapy ivonescimab, which is being developed by Summit Therapeutics in partnership with Akeso. In…
    BioPharma Dive · 9h agoRegulatoryNegative↗ source
  • Pfizer CEO warns China will be major biotech competitor by 2030 and urges AI-driven cost cuts
    At the Jefferies Global Healthcare Conference in London, Pfizer chief Albert Bourla said China is rapidly building its biotech sector and could become the company's biggest rival by 2030, surpassin…
    BioSpace · 10h agoNeutral↗ source
  • FDA rejects Summit Therapeutics' ivonescimab, citing trial design and safety concerns
    Summit Therapeutics received a Complete Response Letter from the FDA rejecting its application for ivonescimab, a PD-1xVEGF combination intended for EGFR-mutated non-small cell lung cancer. The ag…
    BioSpace · 10h agoRegulatoryNegative↗ source
  • Acquisitions can tie big pharma to existing biotech partners, creating co-parenting challenges
    Acquiring a biotech that already works with another large pharmaceutical firm can bring extra obligations beyond the technology and pipeline being bought. The report highlights Merck KGaA’s planne…
    BioSpace · 18h agoDealNeutral↗ source
  • Outset Medical issues safety alert for Tablo dialysis system power cords overheat risk
    The FDA’s Center for Devices and Radiological Health has posted an Early Alert after learning that certain power cords used with Outset Medical’s Tablo hemodialysis consoles and the TabloCart with…
    fda medwatch · 18h agoRegulatoryNeutral↗ source
  • FDA clears Medtronic's MiniMed Fit tubeless insulin pump
    MiniMed, a Medtronic unit, announced that the FDA has granted clearance for its new tubeless insulin pump called MiniMed Fit. The device is designed to be worn for up to seven days and holds a 300…
    Fierce Biotech · 20h agoApprovalPositive↗ source
  • Merck halts $2.7 billion BTK inhibitor program after negative phase 3 data
    Merck announced it is discontinuing its BTK inhibitor nemtabrutinib program, ending three phase 3 trials in chronic lymphocytic leukemia and small lymphocytic lymphoma. The decision follows a reco…
    Fierce Biotech · 20h agoNegative readoutNegative↗ source
  • Big Pharma execs urge biotech firms to be transparent and patient to win deals
    At Fierce Biotech's London Life Sciences Week, representatives from five major pharmaceutical companies shared how they evaluate biotech partners. Bayer's head of business development warned that…
    Fierce Biotech · 21h agoDealNeutral↗ source
  • Experts warn of safety risks as FDA targets compounded GLP-1 weight-loss drugs sold by telehealth firms
    At the HLTH conference, experts highlighted growing concerns about telehealth companies that sell compounded GLP-1 weight-loss medications. These firms create custom formulations and ship them dir…
    BioPharma Dive · 4h agoRegulatoryNegative↗ source
  • White House withdraws Heidi Overton’s FDA commissioner nomination amid Senate opposition
    The White House pulled the nomination of Heidi Overton for FDA commissioner just hours before the Senate Health, Education, Labor, and Pensions (HELP) committee was set to vote. Overton, who serve…
    BioSpace · 21h agoRegulatoryNegative↗ source
  • 8 companies hiring in North Carolina now
    Looking for a biopharma role in North Carolina? Jobs on BioSpace increased significantly year over year in October. Check out the open positions posted now for life sciences professionals like you.
    BioSpace · 9h agoRegulatoryNeutral↗ source
  • BioSpace launches dashboard to track performance of U.S. biotech IPOs in 2026
    BioSpace introduced a new IPO dashboard that monitors U.S. biotech companies that went public in 2026. The tool will be refreshed weekly with the latest closing prices and will add any newly liste…
    BioSpace · 11h agoNeutral↗ source
  • Quanterix CEO Everett Cunningham resigns after ten months, interim leader appointed
    Quanterix announced that Everett Cunningham will leave his role as president and chief executive officer after serving less than a year. The company said he will step down to pursue another opportu…
    Fierce Biotech · 15h agoNeutral↗ source